U.S. Patent 8,658,678: Claim Scope, Expiration, Formulation Coverage, and Metronidazole Patent Landscape

U.S. Patent No. 8,658,678 protects a narrow topical-treatment method using a metronidazole formulation containing 1.25% to 1.5% metronidazole, water, and at least two solvent classes selected from polyols, polyol ethers, and low-carbon organic alcohols. The broadest independent claim is a method claim, not a composition claim. Its practical value depends on whether a marketed product uses the claimed concentration, excipient combination, route of administration, and treatment indication.

The claim set has meaningful formulation specificity but several legal vulnerabilities. The most important are the unusual “responsive to treatment with an azole compound” limitation, the dependence on a particular metronidazole concentration range, the method-of-treatment format, and an apparent inconsistency between claims 7 and 8.

What does U.S. Patent 8,658,678 cover?

The patent covers applying a topical pharmaceutical formulation to skin or mucosa for a dermatologic or mucosal disorder. The formulation must contain:

Required element	Scope
Active ingredient	Metronidazole
Metronidazole concentration	Between 1.25% and 1.5%, presumably w/w unless the specification defines otherwise
Vehicle	Water
Solvent classes	At least two of: polyol, polyol ether, low-carbon organic alcohol
Administration	Applied to skin or mucosa
Disease context	A dermatologic or mucosal disorder responsive to treatment with an azole compound

The claim uses “comprising,” which is an open-ended transition. A formulation may contain additional active ingredients, preservatives, gelling agents, buffers, penetration enhancers, fragrances, surfactants, or other excipients and still fall within the claim if all required elements are present.

The independent claim does not require a specific brand, dosage form, viscosity, pH, package, dosing frequency, or disease such as rosacea. Dependent claim 2 adds once-daily or more frequent administration for a sufficient treatment period.

How broad is claim 1 of Patent 8,658,678?

Claim 1 is chemically and therapeutically narrower than its broad wording suggests.

The concentration limitation is central

A product containing 1.25%, 1.3%, 1.4%, or 1.5% metronidazole is positioned inside the stated range. A conventional 0.75% metronidazole product is outside the literal concentration range. A 1.0% product is also outside the range.

The concentration limitation creates a potentially effective design-around. A competing product at 1.2% or 1.6% would not literally satisfy the stated range, although an equivalence theory could be asserted depending on prosecution history, claim construction, and the technical significance of the concentration boundaries.

At least two solvent classes are required

Claim 1 requires at least two of the following:

A polyol;
A polyol ether; and
A low-carbon organic alcohol.

The claim therefore covers formulations containing:

Polyol plus polyol ether;
Polyol plus low-carbon organic alcohol;
Polyol ether plus low-carbon organic alcohol; or
All three classes.

A formulation containing only water, metronidazole, and one of these solvent classes would not satisfy claim 1 literally.

The dependent claims identify commercially familiar excipients:

Propylene glycol as the polyol;
Polyethylene glycol, including PEG 400, as the polyol ether;
Benzyl alcohol as the low-carbon organic alcohol.

The formulation most directly implicated by the dependent claims would contain metronidazole, water, propylene glycol, PEG 400, and benzyl alcohol.

The azole-response limitation may restrict infringement

Claim 1 requires treatment of a disorder “responsive to treatment with an azole compound.” Metronidazole is a nitroimidazole antimicrobial rather than a conventional antifungal azole such as ketoconazole, miconazole, clotrimazole, or itraconazole.

This language can create a claim-construction issue. A court may treat the limitation as:

A meaningful requirement that the treated condition responds to azole therapy;
A functional statement defining the intended patient population; or
A redundant or scientifically imprecise description that does not materially restrict the claim.

The specification and prosecution history would be important. If the applicant relied on this language to distinguish prior art, the limitation is more likely to carry substantive narrowing force.

What do the dependent claims add?

Claim	Added limitation	Practical effect
2	Application one or more times daily for a duration sufficient to ameliorate the disorder	Narrows the dosing method but leaves duration undefined
3	Infectious disorder	Excludes noninfectious disorders unless they are also infectious
4	Fungal infectious disorder	Narrows claim 3 to fungal disease
5	Human patient	Excludes nonhuman treatment
6	Benzyl alcohol as low-carbon organic alcohol	Identifies one solvent
7	Benzyl alcohol at about 1% w/w	Creates a concentration subrange
8	Benzyl alcohol at about 2% w/w	Appears inconsistent with claim 7 because claim 8 depends from claim 7
9	Propylene glycol as polyol	Identifies a common vehicle component
10	Polyol ether is an ether of an alkylene glycol	Narrows the ether class
11	Polyethylene glycol	Narrows claim 10
12	PEG 400	Identifies a specific molecular-weight grade
13	Water at about 55% or more w/w	Adds a high-water formulation requirement
14	Contains all three solvent classes	Requires a polyol, polyol ether, and low-carbon organic alcohol

Claims 9, 12, 13, and 14 provide the clearest formulation pathways. A product containing propylene glycol, PEG 400, benzyl alcohol, water at or above approximately 55%, and metronidazole within the 1.25% to 1.5% range would be a high-risk profile under the claim set.

Is claim 8 legally consistent with claim 7?

Claim 8 depends on claim 7 and requires benzyl alcohol at about 2% w/w. Claim 7 requires benzyl alcohol at about 1% w/w.

Under ordinary dependency rules, claim 8 incorporates every limitation of claim 7. That produces a potential contradiction: claim 8 would require benzyl alcohol at both approximately 1% and approximately 2%.

Possible interpretations include:

“About 1%” is broad enough to encompass 2%;
Claim 8 contains a drafting error;
Claim 8 was intended to depend directly from claim 6 or claim 1;
The claims may be construed in light of the specification to identify separate embodiments.

The contradiction may affect enforceability or claim construction. It does not necessarily invalidate the entire patent, but it weakens reliance on claim 8 as an independent commercial coverage position.

What formulations are protected by Patent 8,658,678?

The strongest literal coverage appears to involve high-water, solvent-rich formulations with metronidazole in the 1.25% to 1.5% range.

Representative covered formulation profile

Component	Claimed profile
Metronidazole	1.25% to 1.5%
Water	Present; claim 13 adds approximately 55% or more
Propylene glycol	Covered under claim 9
PEG 400	Covered under claim 12
Benzyl alcohol	Covered under claims 6 and 14; approximately 1% or 2% under claims 7 and 8
Dosage form	Not expressly limited, but a topical formulation is required
Route	Skin or mucosa

The patent does not appear, from the supplied claims, to require a gel, cream, lotion, foam, ointment, spray, or solution. A product in any of those forms could potentially satisfy the claims if its formulation and use meet the limitations.

Potentially excluded formulations

The following profiles are outside the literal scope of claim 1 unless other facts support an equivalence argument:

Metronidazole below 1.25%;
Metronidazole above 1.5%;
A formulation without water;
A formulation containing only one qualifying solvent class;
An oral formulation;
A product applied only to intact nonmucosal surfaces if the claimed disorder and route are not met;
A product used for a condition not responsive to azole treatment;
A product whose excipients do not include at least two of the specified solvent categories.

How does the patent compare with existing metronidazole products?

The commercial metronidazole topical market historically includes 0.75% and 1% products used for rosacea and related dermatologic conditions. Those products do not automatically fall within Patent 8,658,678 because claim 1 requires 1.25% to 1.5% metronidazole.

Product category	Typical concentration profile	Direct claim 1 risk
Conventional metronidazole gel	Approximately 0.75%	Generally outside concentration range
Conventional metronidazole cream or lotion	Approximately 0.75% to 1%	Generally outside concentration range
Higher-strength metronidazole topical product	1.25% to 1.5%	Potentially high
Metronidazole formulation with propylene glycol and PEG 400	Depends on concentration and water content	Potentially high
Metronidazole formulation with only one listed solvent class	Any concentration	Outside literal “at least two” limitation
Oral metronidazole	Variable	Outside topical route

The patent is therefore not a blanket patent on metronidazole dermatology products. It targets a specific concentration band and excipient architecture.

What is the Orange Book status of Patent 8,658,678?

A method-of-treatment patent is not automatically listed in the FDA Orange Book. Listing depends on whether the patent claims an approved drug product, an approved method of use, or both, and whether the NDA holder submits the patent in accordance with FDA regulations.

The supplied claims do not identify:

An NDA number;
A branded product;
A specific FDA-approved indication;
A dosage form tied to an approved product;
An Orange Book listing date;
A Paragraph IV notice;
A patent-use code.

The claims could support a method-of-use listing if they correspond to an FDA-approved indication and product. They do not, by themselves, establish Orange Book listing status. The Orange Book distinguishes listed patents from the broader universe of issued pharmaceutical patents. [2]

When does Patent 8,658,678 expire?

The patent issued in 2014. Under the Hatch-Waxman patent-term framework, a U.S. utility patent generally expires 20 years from the earliest effective nonprovisional U.S. filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and priority claims. [3]

The issue date alone does not establish the expiration date. The following events can change the projected term:

A prior U.S. nonprovisional priority filing;
Patent-term adjustment;
Patent-term extension under 35 U.S.C. § 156;
A terminal disclaimer;
A reexamination certificate or post-grant proceeding;
A corrected patent term reflected in USPTO records.

The patent should therefore be treated as a live issued patent during its ordinary statutory term unless the official USPTO record establishes expiration, disclaimer, or cancellation. The patent’s commercial blocking period is separate from FDA exclusivity. A patent can remain in force after regulatory exclusivity ends.

What Paragraph IV challenges could target this patent?

A generic or follow-on applicant could challenge the patent through a Paragraph IV certification if the patent is listed for the relevant reference product. Potential invalidity theories would likely focus on:

Anticipation

A challenger would search for a single reference disclosing:

Metronidazole at 1.25% to 1.5%;
Water;
At least two of the listed solvent classes;
Topical treatment of a qualifying disorder.

Prior art disclosing 0.75% or 1% metronidazole alone would not anticipate the full concentration limitation.

Obviousness

Obviousness would likely be the principal challenge. The challenger could combine:

Earlier metronidazole topical products;
Published formulation work using propylene glycol, PEG 400, benzyl alcohol, or related solvents;
Routine concentration optimization;
Known treatment of dermatologic or mucosal disorders.

The patent owner would argue that the claimed concentration and solvent combination produced an unexpected benefit, such as improved stability, tolerability, penetration, spreadability, preservative performance, or clinical efficacy.

Written description and enablement

The claims cover multiple solvent combinations and a broad class of dermatologic or mucosal disorders. A challenger could argue that the specification does not adequately support the full genus or enable every claimed formulation and disorder.

Indefiniteness

Potential pressure points include:

“Between 1.25% and 1.5%” if the endpoints are not defined;
“About 1%” and “about 2%”;
“Low carbon organic alcohol”;
“Responsive to treatment with an azole compound”;
“A duration sufficient to ameliorate the disorder.”

Claim 8’s apparent dependency inconsistency provides a separate drafting issue.

How strong is the patent estate?

The patent has moderate formulation specificity but limited breadth.

Strength factor	Assessment
Concentration limitation	Strong narrowing limitation; creates design-around options
Solvent combination	Provides formulation-specific coverage
Method-of-use format	Requires proof of use or induced use, not merely possession of composition
Dependent formulation claims	Useful against products with matching excipient profiles
Claim 14	Strongest direct formulation combination, but narrow
Claim 8	Weakened by apparent dependency inconsistency
Conventional 0.75% products	Generally outside literal scope
Generic substitution risk	Material if competitors alter concentration or solvent architecture
Manufacturing barrier	Likely limited unless the formulation process is separately claimed
Biosimilar relevance	None; metronidazole is a small-molecule active ingredient

The claims do not appear to create a broad platform monopoly over topical metronidazole. Their commercial value is concentrated in a particular higher-strength formulation and its use.

What manufacturing and geographic barriers apply?

The supplied claims are product-use claims rather than process claims. They do not require a specific manufacturing sequence, mixing temperature, particle-size distribution, filling process, or packaging system.

A competitor could potentially avoid infringement by changing:

Metronidazole concentration;
One or more solvent classes;
Water content;
The dosage form;
The route or labeled indication;
The treatment instructions.

Geographically, the patent provides protection only in the United States. Parallel foreign patent families would require separate analysis. U.S. infringement generally requires making, using, selling, offering to sell, or importing the claimed method or a product used in a manner that satisfies the statutory requirements. The existence of a foreign counterpart would not extend U.S. patent rights.

What litigation and settlement risks should be assessed?

The supplied information does not establish a particular infringement action, Paragraph IV notice, settlement agreement, consent judgment, or final validity ruling involving Patent 8,658,678. The litigation risk analysis therefore turns on the product profile:

A 1.3% metronidazole topical product using propylene glycol, PEG 400, benzyl alcohol, and high water content presents the highest risk.
A 0.75% or 1% product presents a lower literal infringement risk under claim 1.
A product using only one qualifying solvent class presents a separate design-around position.
A product marketed for a noninfectious or non-azole-responsive condition may raise claim-scope defenses, although promotional materials and prescribing information could affect induced-infringement analysis.
A product sold for mucosal use may still fall within the claims because the patent expressly covers mucosa.

Key Takeaways

Patent 8,658,678 is a narrow method patent focused on topical or mucosal metronidazole at 1.25% to 1.5%.
Claim 1 requires water and at least two solvent classes: polyol, polyol ether, and low-carbon organic alcohol.
The strongest formulation profile is metronidazole with water, propylene glycol, PEG 400, and benzyl alcohol.
Conventional 0.75% and 1% metronidazole products are generally outside the literal concentration range.
Claims 9, 12, 13, and 14 provide the most commercially specific formulation coverage.
Claim 8 appears internally inconsistent because it depends on a claim requiring approximately 1% benzyl alcohol while adding approximately 2%.
The patent is not a biosimilar issue and does not create a general monopoly over topical metronidazole.
Orange Book status, exact expiration, Paragraph IV activity, and litigation history cannot be established from the claim text alone.
The primary generic-entry strategy would be to modify concentration, solvent class, dosage form, or labeled use.

FAQs

Does Patent 8,658,678 cover 0.75% metronidazole gel?

Generally no. Claim 1 requires metronidazole at a concentration between 1.25% and 1.5%. A 0.75% formulation would ordinarily fall outside that limitation.

Does the patent cover metronidazole cream as well as gel?

Potentially. The supplied claims do not limit the formulation to a gel. A cream, lotion, solution, or other topical dosage form could fall within the claims if it satisfies the concentration, water, solvent, and treatment limitations.

Can a generic avoid the patent by removing PEG 400?

Potentially. PEG 400 is required only by dependent claim 12. Removing PEG 400 does not avoid claim 1 if the product still contains another polyol ether or at least two qualifying solvent classes. Removing the entire polyol-ether class could avoid certain claims but would not necessarily avoid claim 1 if the product contains a polyol and low-carbon organic alcohol.

Is metronidazole an azole compound for purposes of the claims?

Metronidazole is structurally a nitroimidazole, not a conventional antifungal azole. The legal effect of the claim language depends on the patent specification, prosecution history, and judicial construction of “responsive to treatment with an azole compound.”

Does the patent protect the manufacturing process for the formulation?

Not based on the supplied claims. The claims recite a treatment method and formulation characteristics. They do not recite a specific manufacturing process.

What is the most important design-around feature?

The metronidazole concentration range is the clearest design-around feature. A product below 1.25% or above 1.5% would not literally satisfy that limitation, subject to any doctrine-of-equivalents analysis.

References

United States Patent No. 8,658,678, claims 1–14 (2014).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. [Orange Book]. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension. https://www.uspto.gov/patents/laws/patent-term-calculator
U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the Orange Book and patent listing. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-resources-0

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alembic Therap	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	8,658,678	⤷ Start Trial				TREATMENT OF BACTERIAL VAGINOSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	070406	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2009097143	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,658,678

Which drugs does patent 8,658,678 protect, and when does it expire?

Summary for Patent: 8,658,678